MX2023003867A - Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. - Google Patents

Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.

Info

Publication number
MX2023003867A
MX2023003867A MX2023003867A MX2023003867A MX2023003867A MX 2023003867 A MX2023003867 A MX 2023003867A MX 2023003867 A MX2023003867 A MX 2023003867A MX 2023003867 A MX2023003867 A MX 2023003867A MX 2023003867 A MX2023003867 A MX 2023003867A
Authority
MX
Mexico
Prior art keywords
melanoma
encorafenib
binimetinib
adjuvant treatment
combination
Prior art date
Application number
MX2023003867A
Other languages
English (en)
Inventor
Jean-Claude Vedovato
Jeanne Suissa
Olivier Provendier
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2023003867A publication Critical patent/MX2023003867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica para usarse a manera de tratamiento adyuvante después de la resección de un melanoma, en donde el melanoma que se ha resecado es melanoma en etapa II, y en donde la combinación farmacéutica comprende cantidades terapéuticamente eficaces, indistintamente de: a. encorafenib o una sal farmacéuticamente aceptable del mismo; b. binimetinib o una sal farmacéuticamente aceptable del mismo; y opcionalmente, al menos un vehículo farmacéuticamente aceptable.
MX2023003867A 2020-10-05 2021-10-05 Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. MX2023003867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20306154 2020-10-05
PCT/EP2021/077466 WO2022074011A1 (en) 2020-10-05 2021-10-05 Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma

Publications (1)

Publication Number Publication Date
MX2023003867A true MX2023003867A (es) 2023-04-18

Family

ID=72944083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003867A MX2023003867A (es) 2020-10-05 2021-10-05 Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.

Country Status (4)

Country Link
EP (1) EP4225307A1 (es)
AU (1) AU2021358394A1 (es)
MX (1) MX2023003867A (es)
WO (1) WO2022074011A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335276T3 (es) 2002-03-13 2010-03-24 Array Biopharma, Inc. Derivados de bencimidazol alquilado n3 como inhibidores de mek.
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
EP3702351B1 (en) 2012-10-19 2023-11-22 Array Biopharma, Inc. Formulation comprising a mek inhibitor

Also Published As

Publication number Publication date
WO2022074011A1 (en) 2022-04-14
AU2021358394A1 (en) 2023-04-13
EP4225307A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
SG164378A1 (en) Compounds for the treatment of proliferative disorders
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
MX2022008487A (es) Degradadores de smarca2-vhl.
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
MX2023003867A (es) Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
WO2023141432A3 (en) Apol1 inhibitors and methods of use
ZA202301143B (en) Novel dioxoloisoquinolinone derivatives and use thereof
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
WO2022115381A8 (en) Compositions and methods for treating cns disorders
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
WO2021133894A8 (en) Btk inhibitors
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).